Novartis | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.18B 349M 2025-03
Amgen USD 8.03B 782M 2025-06
AstraZeneca USD 7.06B 1.83B 2025-06
Bausch Health Companies USD 1.73B 593M 2025-06
Biogen USD 2.76B 160.5M 2025-06
Bristol-Myers Squibb USD 12.6B 1.72B 2025-06
Canopy Growth CAD 16.31M 69.8M 2024-12
Corcept Therapeutics USD 102.74M 12.93M 2025-06
Drreddys Laboratories INR 1.1B 743M 2024-12
Eli Lilly USD 3.38B 282.6M 2025-06
Gilead Sciences USD 5.14B 2.78B 2025-06
GlaxoSmithKline GBP 3.6B 865M 2025-06
Glaxosmithkline GBP 3.87B 678M 2024-12
J&J USD 38.47B 32.35B 2025-03
Merck USD 8.01B 622M 2025-06
Novartis USD 6.66B 410M 2025-06
Novartis USD 11.46B 2.15B 2024-12
Pacira USD 300.48M 16.87M 2025-06
Perrigo USD 454.2M 44.3M 2025-06
Pfizer USD 1.64B 208M 2025-06
Prestige Brands USD 139.5M 41.62M 2025-06
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 15.36B 7.37B 2025-06
Sanofi 7.44B 646M 2024-12
Supernus Pharmaceuticals USD 144.71M 28.86M 2025-06
Zoetis USD 1.44B 286M 2025-06


Novartis Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Aug 2025.